This therapy specifically targets and revitalizes exhausted PD‐1+CD8+ T cells by correcting mitochondrial depolarization, underscoring the potential of targeting mitochondrial metabolism to augment CD8+ T cell efficacy in cancer treatment.[107] Genetic engineering is effective in modulating mitochondrial function in CAR‐T cells. The gene discussed is CD8A; the disease is cancer.